In Vivo Pharmacodynamic Method to Assess Complement C5a Receptor Antagonist Efficacy

Area of Science:

• Immunology
• Pharmacology
• Drug Development

Background:

• Complement C5a receptor 1 (C5aR1) is a therapeutic target for autoimmune and inflammatory diseases.
• Understanding pharmacokinetics and pharmacodynamics is crucial for preclinical drug development and clinical dose selection.
• Few in vivo pharmacodynamic methods exist for C5a inhibitors.

Purpose of the Study:

• To develop a comprehensive in vivo pharmacodynamic assay for C5aR1 inhibitors in mice.
• To apply this assay to evaluate the peptide-based C5aR1 antagonists PMX53 and JPE-1375.
• To establish a pharmacokinetic/pharmacodynamic model for C5aR1 inhibitors.

Main Methods:

• Developed and validated an in vivo pharmacodynamic assay in mice using recombinant mouse C5a.
• Utilized C5a receptor-deficient mice to confirm C5aR1-mediated responses.
• Administered PMX53 and JPE-1375 intravenously to assess their in vivo efficacy and duration.

Main Results:

• Intravenous C5a induced rapid neutrophil mobilization and TNF elevation, primarily via C5aR1.
• Both PMX53 and JPE-1375 inhibited C5aR1-mediated responses at 1 mg/kg.
• PMX53 demonstrated a significantly longer in vivo active duration (up to 6 h) compared to JPE-1375 (<2 h).

Conclusions:

• A robust in vivo pharmacodynamic model for C5aR1 inhibitors was established in mice.
• Pharmacokinetic analysis revealed differences in half-life, with PMX53 having a longer duration of action.
• This model can aid preclinical translational studies for therapeutic drug candidates targeting C5a and C5aR1.